| Immune response and immunopathology during toxoplasmosis CD Dupont, DA Christian, CA Hunter Seminars in immunopathology 34, 793-813, 2012 | 436 | 2012 |
| Interleukin-27 priming of T cells controls IL-17 production in trans via induction of the ligand PD-L1 K Hirahara, K Ghoreschi, XP Yang, H Takahashi, A Laurence, G Vahedi, ... Immunity 36 (6), 1017-1030, 2012 | 305 | 2012 |
| Parasite Fate and Involvement of Infected Cells in the Induction of CD4+ and CD8+ T Cell Responses to Toxoplasma gondii CD Dupont, DA Christian, EM Selleck, M Pepper, M Leney-Greene, ... PLoS pathogens 10 (4), e1004047, 2014 | 102 | 2014 |
| Virulence of Toxoplasma gondii is associated with distinct dendritic cell responses and reduced numbers of activated CD8+ T cells ED Tait, KA Jordan, CD Dupont, TH Harris, B Gregg, EH Wilson, ... The Journal of Immunology 185 (3), 1502-1512, 2010 | 74 | 2010 |
| A host GPCR signaling network required for the cytolysis of infected cells facilitates release of apicomplexan parasites MG Millholland, S Mishra, CD Dupont, MS Love, B Patel, D Shilling, ... Cell host & microbe 13 (1), 15-28, 2013 | 51 | 2013 |
| African trypanosomes contain 5-methylcytosine in nuclear DNA KT Militello, P Wang, SK Jayakar, RL Pietrasik, CD Dupont, K Dodd, ... Eukaryotic cell 7 (11), 2012-2016, 2008 | 42 | 2008 |
| Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody RB Gombos, A Gonzalez, M Manrique, D Chand, D Savitsky, B Morin, ... PLoS One 13 (4), e0191926, 2018 | 24 | 2018 |
| Two Vaccines for Staphylococcus aureus Induce a B-Cell-Mediated Immune Response CD Dupont, IL Scully, RM Zimnisky, B Monian, CP Rossitto, EB O'Connell, ... MSphere 3 (4), 10.1128/msphere. 00217-18, 2018 | 18 | 2018 |
| Flt3 ligand is essential for survival and protective immune responses during toxoplasmosis CD Dupont, G Harms Pritchard, S Hidano, DA Christian, S Wagage, ... The Journal of Immunology 195 (9), 4369-4377, 2015 | 16 | 2015 |
| Role of the NF-κB transcription factor c-Rel in the generation of CD8+ T-cell responses to Toxoplasma gondii KA Jordan, CD Dupont, ED Tait, HC Liou, CA Hunter International immunology 22 (11), 851-861, 2010 | 16 | 2010 |
| Guanylate-binding proteins: niche recruiters for antimicrobial effectors CD Dupont, CA Hunter Immunity 37 (2), 191-193, 2012 | 14 | 2012 |
| Longitudinal multiparameter single-cell analysis of macaques immunized with pneumococcal protein-conjugated or unconjugated polysaccharide vaccines reveals distinct antigen … B Jia, LK McNeil, CD Dupont, K Tsioris, RM Barry, IL Scully, AO Ogunniyi, ... PLoS One 12 (9), e0183738, 2017 | 13 | 2017 |
| Phase I/Ii, open-label, multiple ascending dose trial of Agen2034, an anti–Pd-1 monoclonal antibody, in advanced solid malignancies: Results of dose escalation in advanced … C Drescher, KN Moore, JF Liu, DM O’Malley, EW Wang, JSZ Wang, ... Annals of Oncology 29, viii412-viii413, 2018 | 10 | 2018 |
| Phase 1/2 open-label, multiple ascending dose trial of AGEN2034, an anti-PD-1 monoclonal antibody, in advanced solid malignancies: Results of dose escalation. KN Moore, C Dresher, J Liu, DM O'Malley, EW Wang, JSZ Wang, ... Journal of Clinical Oncology 36 (15_suppl), 3086-3086, 2018 | 7 | 2018 |
| 511 Initial results of a phase 1 study of intratumoral ONCR-177, an oncolytic herpes-simplex virus-1 expressing five immunomodulatory transgenes, in subjects with advanced … JC Park, H Soliman, G Falchook, T Owonikoko, A Spreafico, E Massarelli, ... Journal for ImmunoTherapy of Cancer 9 (Suppl 2), 2021 | 6 | 2021 |
| Evaluation of peripheral T cell subset proliferation as a pharmacodynamic assay to guide the development of anti-CTLA-4 and PD-1 antibody combinations in patients with solid tumors P De Souza, A Malczewski, I Proscurshim, G Yuan, E Coart, C Dupont, ... CANCER RESEARCH 78 (13), 2018 | 5 | 2018 |
| Abstract CT104: Evaluation of peripheral T cell subset proliferation as a pharmacodynamic assay to guide the development of anti-CTLA-4 and PD-1 antibody combinations in … PD Souza, A Malczewski, I Proscurshim, G Yuan, E Coart, C Dupont, ... Cancer Research 78 (13_Supplement), CT104-CT104, 2018 | 4 | 2018 |
| Phase I/II study of CTLA-4 inhibitor AGEN1884+ PD-1 Inhibitor AGEN2034 in patients with advanced/refractory solid tumors, with expansion into 2L cervical cancer and solid tumors J Coward, C Lemech, T Meniawy, CD Dupont, AM Gonzalez, M Lim, ... Annals of Oncology 29, viii417, 2018 | 3 | 2018 |
| Phase I open-label, ascending dose trial of AGEN1884, an anti-CTLA-4 monoclonal antibody, in advanced solid malignancies: Dose selection for combination with PD-1 blockade. BA Wilky, P Kumthekar, R Wesolowski, JJ Hwang, SI Park, I Proscurshim, ... Journal of Clinical Oncology 36 (15_suppl), 3075-3075, 2018 | 3 | 2018 |
| Detection and characterization of fibrin/amyloid microclots in patients with post-acute sequelae of Covid-19 M Walker, EM Federico, DB Kell, C Dupont, A Proal, E Pretorius Circulation 146 (Suppl_1), A15637-A15637, 2022 | 2 | 2022 |